Posted by Michael Wonder on 16 Feb 2024
Caliway received US FDA fast track designation for CBL-514 for the treatment of Dercum's disease
14 February 2024 - CBL-514 is the first drug to receive fast track designation for Dercum's disease treatment.
Caliway Biopharmaceuticals announced that the US FDA has granted fast track designation for the investigation of CBL-514 in Dercum's disease treatment.
